A Phase 1, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of PALI-2108 in Healthy Volunteers and Open-Label Study of a Patient Cohort With Ulcerative Colitis
Latest Information Update: 13 Nov 2025
At a glance
- Drugs PALI 2108 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; First in man
- Sponsors Palisade Bio
Most Recent Events
- 13 Oct 2025 According to a Palisade Bio media release,topline data expected in Q1 2026.
- 17 Sep 2025 Results presented at Palisade Bio media release.
- 17 Sep 2025 According to a Palisade Bio media release, Patient dosing in the Phase 1b FSCD study is expected to begin in 2H 2025.